California legislature ramps up transparency pressure on Kaiser Permanente

Amid a standoff between 85,000 California-based workers at Kaiser Permanente and the health system over contract negotiations, the California legislature has ramped up the pressure against the nonprofit healthcare services organization.

The California Assembly passed SB 343 on Aug. 22, which would require the organization to be more transparent about justifying its health insurance premiums, similar to other insurance companies. It would also have to provide more information on the individual hospital level instead of lumping data together by region.

The bill, which heads back to the California senate for a full vote, is supported by many organizations and boards, including the union representing Kaiser workers.

Earlier this month, Kaiser workers based in California voted to strike in October after labor negotiations disintegrated over the previous months. Workers complained that the nonprofit was paying executives too much, was too opaque and didn’t offer enough Medicaid services.

“With all the important healthcare reforms over the last decade, transparency around pricing is one that still needs improvement in California,” Evelia Rodriguez, a records clerk at Kaiser Permanente in Los Angeles, said in a statement. “No healthcare provider, especially one as large and important as Kaiser, should be able to avoid the kind of scrutiny consumers, employers, unions and regulators need to protect themselves and the public.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.